BioCentury
ARTICLE | Company News

Par Pharmaceutical infectious, cancer, endocrine news

July 4, 2011 7:00 AM UTC

Par will restructure and reduce headcount by about 100 in its Strativa Pharmaceuticals unit. The company said most of the cuts would come from the Strativa sales force. Par said Strativa will focus on the sale of Par's marketed drugs Megace ES megestrol acetate and Nascobal cyanocobalamin. Par said the restructuring will reduce expenses by about $8-$12 million for the remainder of 2011. Par formed Strativa in 2007 as its pharmaceuticals division to market Megace ES and develop drugs in HIV and oncology indications (see BioCentury, Oct. 8, 2007). ...